We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Fresenius Kabi Expands Into Biosimilars With $547M Stake in mAbxience
Fresenius Kabi Expands Into Biosimilars With $547M Stake in mAbxience
German device manufacturer Fresenius Kabi is acquiring a majority stake in mAbxience, the biosimilars division of Madrid, Spain-based Insud Pharma, for $547 million.